Drug · Small Molecule

Dexamethasone

CI-DRUG-00000186Explore in graph →NCIt C422 CHEMBL384467 CIViC Approved

Regulatory

Approvals (11)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

emaRegulatory11 approval records from 2 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
EU EMA	Multiple Myeloma	Treatment of multiple myeloma.	approved	Mar 16, 2016	ema
US FDA	—

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	388	175	329	1,446	11	EU, US	Jun 20, 1962	1990-01
Non-Hodgkin Lymphoma	Approved	Phase 4	259	110	168	832	2	EU, US	Mar 16, 2016	1993-03
Multiple Myeloma	Approved	Phase 4	212	85	143	676	2	EU, US	Mar 16, 2016	1994-01
Leukemia	Phase4	Phase 4	67	38	58	232	0	—

Curated evidence

Clinical evidence (5)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–5 of 5 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ABL1 Fusion1
Dasatinib + Dexamethasone

Clinical trials

Trials with this intervention (1,461)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 51–100 of 1,461 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04216524	Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm	recruiting	Phase 2	40	M.D. Anderson Cancer CenterOTHER	1	Sep 14, 2026	clinicaltrials
NCT06953960	A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Molecule

Record

Kind: Small Molecule
Mechanism: Glucocorticoid receptor agonist
Targets: 1 gene
UNII: AI9376Y64P
Aliases: (11Beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione, 16Alpha-methyl-9alpha-fluoro-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione, 16Alpha-methyl-9alpha-fluoro-delta1-hydrocortisone, 16Alpha-methyl-9alpha-fluoroprednisolone, 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone, 9Alpha-fluoro-11beta,17alpha,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione, 9Alpha-fluoro-16alpha-methylprednisolone, Aacidexam, Adexone, Aeroseb-dex, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul Mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decaderm, Decadrol, Decadron, Decadron-75, Decadron DP … (+94)

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (2)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	H02AB02	Corticosteroids for systemic use